Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2013 Mar;42(2):198-201.
doi: 10.1097/MPA.0b013e3182592c96.

Prevalence of diabetes mellitus in pancreatic cancer compared to common cancers

Gaurav Aggarwal  1 , Pratima Kamada, Suresh T Chari
Affiliations
Comparative Study

Prevalence of diabetes mellitus in pancreatic cancer compared to common cancers

Gaurav Aggarwal et al. Pancreas. 2013 Mar.

Abstract

Objectives: In pancreatic cancer (PaC), the prevalence of diabetes mellitus (DM), especially new-onset DM (≤36 months of PaC diagnosis), is high. To determine if this observation is unique to PaC, we compared the prevalence and characteristics of DM in lung, breast, prostate, and colorectal cancers with PaC and noncancer controls.

Methods: We retrospectively reviewed the medical records of 500 consecutive patients with cancer (100 each with lung, breast, prostate, and colorectal cancers and PaC) and 100 noncancer controls.

Results: Patients with PaC (mean age ± SD, 71.6 ± 9.4 years; 53% men) had a significantly (P < 0.0001) higher prevalence of DM (68%) compared to age-matched patients with lung (mean age ± SD, 71.6 ± 9.4 years; 59% men; and 19.6% DM), breast (mean age ± SD, 71.6 ± 9.6 years; 100% women; and 19.4% DM), prostate (mean age ± SD, 71.3 ± 9.4 years; 100% men; and 14.8% DM), and colorectal cancer (mean age ± SD, 71.6 ± 9.5 years; 56% men; and 20.7% DM), and noncancer controls (mean age ± SD, 70.7 ± 9.2 years; 57% men; and 23.5% DM). Among the patients with PaC, 40% developed DM in the 36 months preceding the diagnosis of PaC compared with 3.3% to 5.7% in the other groups (P < 0.0001).

Conclusions: Whereas the prevalence of DM in PaC is very high, DM prevalence in other common cancers is no different from that in noncancer controls. In particular, new-onset DM is a phenomenon that is unique to PaC.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Prevalence of DM in various cancers and non-cancer controls
Figure 2
Figure 2
Prevalence of new-onset DM in various cancers and non-cancer controls
See this image and copyright information in PMC

References

    1. Centers for Disease Control and Prevention . National Diabetes Fact Sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; Atlanta, GA: 2011.
    1. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047–53. - PubMed
    1. Altekruse SF, Kosary CL, Krapcho M, et al., editors. SEER Cancer Statistics Review, 1976-2007. National Cancer Institute; Bethesda, MD: [Accessed on June 1, 2011]. 2010. based on November 2009 SEER data submission, posted to the SEER Web site. Available at: http://www.cancer.org/cancer/cancerbasics/cancer-prevalence.
    1. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care. 2010;33(7):1674–85. - PMC - PubMed
    1. Vigneri P, Frasca F, Sciacca L, et al. Diabetes and cancer. Endocr Relat Cancer. 2009;16:1103–1123. - PubMed

Publication types

MeSH terms